These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 31141112)

  • 1. Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
    Ecker BL; Vollmer CM; Behrman SW; Allegrini V; Aversa J; Ball CG; Barrows CE; Berger AC; Cagigas MN; Christein JD; Dixon E; Fisher WE; Freedman-Weiss M; Guzman-Pruneda F; Hollis RH; House MG; Kent TS; Kowalsky SJ; Malleo G; Salem RR; Salvia R; Schmidt CR; Seykora TF; Zheng R; Zureikat AH; Dickson PV
    JAMA Surg; 2019 Aug; 154(8):706-714. PubMed ID: 31141112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study.
    Moekotte AL; Malleo G; van Roessel S; Bonds M; Halimi A; Zarantonello L; Napoli N; Dreyer SB; Wellner UF; Bolm L; Mavroeidis VK; Robinson S; Khalil K; Ferraro D; Mortimer MC; Harris S; Al-Sarireh B; Fusai GK; Roberts KJ; Fontana M; White SA; Soonawalla Z; Jamieson NB; Boggi U; Alseidi A; Shablak A; Wilmink JW; Primrose JN; Salvia R; Bassi C; Besselink MG; Abu Hilal M
    Br J Surg; 2020 Aug; 107(9):1171-1182. PubMed ID: 32259295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
    Jin Z; Hartgers ML; Sanhueza CT; Shubert CR; Alberts SR; Truty MJ; Muppa P; Nagorney DM; Smyrk TC; Hassan M; Mahipal A
    Eur J Surg Oncol; 2018 May; 44(5):677-683. PubMed ID: 29506768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma.
    Showalter TN; Zhan T; Anne PR; Chervoneva I; Mitchell EP; Yeo CJ; Rosato EL; Kennedy EP; Berger AC
    J Gastrointest Surg; 2011 Aug; 15(8):1411-6. PubMed ID: 21523621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant radiotherapy following pancreaticoduodenectomy for ampullary adenocarcinoma improves survival in node-positive patients: a propensity score analysis.
    Kamarajah SK
    Clin Transl Oncol; 2018 Sep; 20(9):1212-1218. PubMed ID: 29497964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Approach to Adenocarcinoma of the Ampulla of Vater.
    Patel M; Uboha NV
    Curr Treat Options Oncol; 2021 Sep; 22(11):103. PubMed ID: 34586537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy.
    Palta M; Patel P; Broadwater G; Willett C; Pepek J; Tyler D; Zafar SY; Uronis H; Hurwitz H; White R; Czito B
    Ann Surg Oncol; 2012 May; 19(5):1535-40. PubMed ID: 22045467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
    Shoji H; Morizane C; Hiraoka N; Kondo S; Ueno H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
    Jpn J Clin Oncol; 2014 Apr; 44(4):324-30. PubMed ID: 24482413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas - are outcomes different in intestinal and pancreatobiliary subtypes with adjuvant gemcitabine?
    Ramaswamy A; Bhandare M; Bal M; Shrirangwar S; Kataria P; Majumdar S; Swami R; Rohila J; Chaudhari V; Mandavkar S; Chavan N; Shrikhande SV; Ostwal V
    HPB (Oxford); 2020 Mar; 22(3):376-382. PubMed ID: 31405778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic score for recurrence after Whipple's pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort.
    Colussi O; Voron T; Pozet A; Hammel P; Sauvanet A; Bachet JB; Vaillant JC; Rougier P; Nordlinger B; Berger A; Coriat R; Dousset B; Malka D; André T; Paye F; Aparicio T; Locher C; Cojean Zeleck D; Tchinou L; Bonnetain F; Taieb J
    Eur J Surg Oncol; 2015 Apr; 41(4):520-6. PubMed ID: 25680954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer.
    Kim WS; Choi DW; Choi SH; Heo JS; You DD; Lee HG
    J Surg Oncol; 2012 Mar; 105(3):266-72. PubMed ID: 21882202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy is associated with improved overall survival in patients with pancreatobiliary or mixed subtype ampullary cancer after pancreatoduodenectomy - A multicenter cohort study.
    Bolm L; Ohrner K; Nappo G; Rückert F; Zimmermann C; Rau BM; Petrova E; Honselmann KC; Lapshyn H; Bausch D; Weitz J; Sandini M; Keck T; Zerbi A; Distler M; Wellner UF
    Pancreatology; 2020 Apr; 20(3):433-441. PubMed ID: 31987649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    You DD; Lee HG; Heo JS; Choi SH; Choi DW
    J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    Neoptolemos JP; Moore MJ; Cox TF; Valle JW; Palmer DH; McDonald AC; Carter R; Tebbutt NC; Dervenis C; Smith D; Glimelius B; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Ghaneh P; Halloran CM; Lerch MM; Oláh A; Rawcliffe CL; Verbeke CS; Campbell F; Büchler MW;
    JAMA; 2012 Jul; 308(2):147-56. PubMed ID: 22782416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database.
    Ecker BL; McMillan MT; Datta J; Lee MK; Karakousis GC; Vollmer CM; Drebin JA; Fraker DL; Roses RE
    Cancer; 2017 May; 123(6):967-976. PubMed ID: 28263387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma.
    Okano K; Oshima M; Yachida S; Kushida Y; Kato K; Kamada H; Wato M; Nishihira T; Fukuda Y; Maeba T; Inoue H; Masaki T; Suzuki Y
    J Surg Oncol; 2014 Aug; 110(2):156-62. PubMed ID: 24619853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma.
    Kim K; Chie EK; Jang JY; Kim SW; Han SW; Oh DY; Im SA; Kim TY; Bang YJ; Ha SW
    Clin Transl Oncol; 2012 May; 14(5):391-5. PubMed ID: 22551547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies?
    Westgaard A; Pomianowska E; Clausen OP; Gladhaug IP
    Ann Surg Oncol; 2013 Feb; 20(2):430-9. PubMed ID: 22956064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the two histological subtypes of ampullary adenocarcinoma: a retrospective study.
    Xu ZY; Guan J; Zhang ZY; Liu DW; Li XD; Zhou ZQ
    Cir Cir; 2024; 92(2):159-164. PubMed ID: 38782386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma.
    Westgaard A; Tafjord S; Farstad IN; Cvancarova M; Eide TJ; Mathisen O; Clausen OP; Gladhaug IP
    BMC Cancer; 2008 Jun; 8():170. PubMed ID: 18547417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.